Diversify Advisory Services LLC Makes New $332,000 Investment in Ascendis Pharma A/S (NASDAQ:ASND)

Diversify Advisory Services LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,991 shares of the biotechnology company's stock, valued at approximately $332,000.

A number of other hedge funds have also bought and sold shares of ASND. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter valued at about $28,000. Quarry LP acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter valued at about $96,000. Tower Research Capital LLC TRC increased its position in Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after purchasing an additional 664 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Ascendis Pharma A/S in the fourth quarter valued at approximately $174,000. Finally, New Wave Wealth Advisors LLC bought a new position in Ascendis Pharma A/S during the first quarter worth $222,000.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ASND. Wedbush increased their target price on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Citigroup lifted their price objective on Ascendis Pharma A/S from $213.00 to $243.00 and gave the company a "buy" rating in a report on Friday, July 11th. Oppenheimer restated an "outperform" rating and set a $224.00 price objective (up previously from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Bank of America boosted their price objective on Ascendis Pharma A/S from $201.00 to $216.00 and gave the company a "buy" rating in a research note on Monday, June 9th. Finally, Morgan Stanley initiated coverage on Ascendis Pharma A/S in a report on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price objective for the company. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $223.07.

Ascendis Pharma A/S Stock Down 1.5%

Ascendis Pharma A/S stock traded down $2.48 on Tuesday, hitting $165.54. The company's stock had a trading volume of 326,520 shares, compared to its average volume of 505,669. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00. The company has a fifty day moving average price of $169.61 and a 200-day moving average price of $154.89. The firm has a market cap of $10.12 billion, a P/E ratio of -26.36 and a beta of 0.38.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. Analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.